Trial reportThe Journal of investigative dermatology2014
Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy.
Trial report in The Journal of investigative dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brazilian guidelines for diagnosis, treatment and follow-up of primary cutaneous melanoma - Part II.Anais brasileiros de dermatologiaGuideline
- Dermoscopic and Histopathological Features of Melanocytic Lesions in Melanoma Patients Undergoing Adjuvant Systemic Therapy.Dermatology practical & conceptual · 2026Article
- Article
- A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib.JAAD case reports · 2022Article
- Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management.International journal of women's dermatology · 2021Review
- New Discoveries and Updates on Cutaneous Adverse Drug Reactions Presented at the 24th World Congress of Dermatology, Milan, Italy, 2019.Drug safety · 2020Article
- Cutaneous toxicities of new treatments for melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.American journal of clinical dermatology · 2018Review
- Eruptive melanocytic nevi associated with ponatinib.JAAD case reports · 2018Article
- Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib.Postepy dermatologii i alergologii · 2018Article
- Management of the cutaneous adverse effects of antimelanoma therapy.Melanoma management · 2017Review
- Review
- Discriminating Nevi from Melanomas: Clues and Pitfalls.Dermatologic clinics · 2016Review
- Biologically distinct subsets of nevi.Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia · 2016Review
- Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma.OncoTargets and therapy · 2016Review
- Genetics of melanocytic nevi.Pigment cell & melanoma research · 2015Review
- Dormant melanomas or changing nevi?The Journal of investigative dermatology · 2014Article
- Treating advanced melanoma: current insights and opportunities.Cancer management and research · 2014Review
- Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.Anais brasileiros de dermatologiaReview
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Second primary melanomas (SPMs) induced by vemurafenib have been recently described. The aim of this study was to define the dermoscopical signs of melanoma in this context. Patients underwent a total body examination before receiving vemurafenib. Each single melanocytic lesion was registered before therapy by digital dermoscopy (DD), and then repeated monthly until therapy disruption. Forty-two patients were included, the mean duration of follow-up was 6.7 months, and a mean number of 51 lesions per patients were captured and followed. A total number of 2,155 lesions were recorded, of which 56.1% presented at least one change during the study. More common changes concerned the color of the lesions (up to 15%) and appearance or disappearance of globules (14.6%). Thirty-six of the melanocytic lesions were surgically excised, 21 were classified as a nevus, 1 was a lentigo, and 14 as a second new primary melanoma (occurring in 21% of our patients). DD allowed us to excise only 36/2,155 (1.6%) of the lesions and permitted us to detect 14 SPM in the 42 patients with a highly efficient malignant/benign ratio of 63.6%. Although vemurafenib is now tested in an adjuvant setting DD should be systematically used in order to accurately detect SPM and reduce the number of unnecessary excisions.
Indexed as
Identifiers
24304815What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.